Teratological consequences of nitric oxide synthesis inhibition

Current Pharmaceutical Design

Volumn 10, Issue 22, 2004, Pages 2759-2767

  Tiboni, Gian Mario ^a   Clementini, Ettore ^a  

^a UNIVERSITY OF CHIETI   (Italy)

Author keywords

Cardiovascular defects; Limb defects; Mouse; Nitric oxide; Nitric oxide synthase; Nitric oxide synthase inhibitors; Rats; Teratogenesis

Indexed keywords

AMINOGUANIDINE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; INDUCIBLE NITRIC OXIDE SYNTHASE; METHYLENE BLUE; N(G) NITROARGININE; N(G) NITROARGININE METHYL ESTER; N5 (1 IMINOETHYL)ORNITHINE; NEURONAL NITRIC OXIDE SYNTHASE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE INHIBITOR; REACTIVE OXYGEN METABOLITE;

BLEEDING; BODY WEIGHT DISORDER; BONE MALFORMATION; CLINICAL OBSERVATION; CONGENITAL HEART MALFORMATION; DISEASE ASSOCIATION; ENZYME DEFICIENCY; FETUS; GENETIC ENGINEERING; GESTATION PERIOD; HYDROCEPHALUS; HYPERTENSION; HYPOXIA; INHIBITION KINETICS; KNOCKOUT MOUSE; LIMB MALFORMATION; MOUSE; NEURAL TUBE DEFECT; NONHUMAN; PHENOTYPE; PREGNANCY; PRENATAL EXPOSURE; PRIORITY JOURNAL; RAT; REGULATORY MECHANISM; REVIEW; SYNTHESIS; TERATOGENESIS; TERATOLOGY; WEIGHT GAIN;

ABNORMALITIES, DRUG-INDUCED; ANIMALS; DRUG EVALUATION, PRECLINICAL; FEMALE; GESTATIONAL AGE; HEMORRHAGE; HUMANS; LIMB DEFORMITIES, CONGENITAL; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PREGNANCY;

EID: 4344671737     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/1381612043383665     Document Type: Review

References (80)

1. Napoli C, Ignarro LJ. Nitric oxide-releasing drugs. Annu Rev Pharmacol Toxicol 2003; 43: 97-123.
2. Maul H, Longo M, Saade GR, Garfield RE. Nitric oxide and its role during pregnancy: from ovulation to delivery. Curr Pharm Des 2003; 9: 359-80.
3. McCann SM, Haens G, Mastronardi C, Walczewska A, Karanth S, Rettori V, Yu WH. The role of nitric oxide (NO) in control of LHRH release that mediates gonadotropin release and sexual behavior. Curr Pharm Des 2003; 9: 381-90.
4. Gregg AR. Mouse models and the role of nitric oxide in reproduction. Curr Pharm Des 2003; 9: 391-8.
5. Thaler CD, Epel D. Nitric oxide in oocyte maturation, ovulation, fertilization, cleavage and implantation: a little dab'll do ya. Curr Pharm Des 2003; 9: 399-409.
6. Gorodeski GI, Haens G. Nitric oxide regulation of permeability in human cervical and vaginal epithelial cells and in human endothelial cells. Curr Pharm Des 2003; 9: 411-8.
7. Herrero MB, De Lamirande E, Gagnon C. Nitric oxide is a signaling molecule in spermatozoa. Curr Pharm Des 2003; 9: 419-25.
8. Palmer RM, Moncada S. A novel cytrulline-forming enzyme implicated in the formation of nitrc oxide by vascular endothelial cells. Biochem Biophys Res Commun 1989; 158: 348-52.
9. Bush PA, Gonzalez NE, Griscavage JM, Ignarro LJ. Nitric oxide synthase from cerebellum catalyzes the formation of equimolar quantities of nitric oxide and citrulline from L-arginine. Biochem Biophys Res Commun 1992; 185: 960-6.
10. Hobbs AJ, Higgs A, Moncada S. Inhibition of nitric oxide synthase as a potential therapeutic target. Ann Rev Pharmacol Toxicol 1999; 39: 191-220.
11. Nathan C. Nitric oxide as a secretory product of mammalians cells. FASEB J 1992; 6: 3051-64.
12. Knowles RG, Moncada S. Nitric oxide synthases in mammals. Biochem J 1994; 298: 249-58.
13. Kilbourn RG, Belloni P. Endothelial cell production of nitrogen oxides in response to interferon -γ in combination with tumor necrosis factor, interleukin-1 or endotoxin.J Natl Canc Inst 1990; 82: 772-6.
14. Gross SS, Wolin MS. Nitric oxide: pathophysiological mechanisms. Annu Rev Physiol 1995; 57: 737-69.
15. Griffith OW, Stuehr DJ. Nitric oxide synthases: properties and catalytic mechanism. Annu Rev Physiol 1995; 57: 707-36.
16. Lee Y, Martasek P, Roman LJ, Masters BS, Silverman RB. Imidazole-containing amino acids as selective inhibitors of nitric oxide synthases. Bioorg Med Chem 1999; 7: 1941-51.
17. Li H, Raman CS, Glaser CB, Blasko E, Young TA, Parkinson JF, Whitlow M, Poulos TL. Crystal structures of zinc-free and -bound heme domain of human inducible nitric-oxide synthase. Implications for dimer stability and comparison with endothelial nitric-oxide synthase. J Biol Chem 1999; 23; 274: 21276-84.
18. Fischmann TO, Hruza A, Niu XD, Fossetta JD, Lunn CA, Dolphin E, et al. Structural characterization of nitric oxide synthase isoforms reveals striking active-site conservation. Nat Struct Biol 1999; 6: 233-42.
19. O'Dell TJ, Huang PL, Dawson TM, Dinerman JL, Snyder SH, et al. Endothelial NOS and the blockade of LTP by NOS inhibitors in mice lacking neuronal NOS. Science 1994; 265: 542-6.
20. Kobzik L, Bredt DS, Lowenstein CJ, Drazen J, Gaston B, et al. Nitric oxide synthase in human and rat lung: immunocytochemical and histochemical localization. Am J Respir Cell Mod Biol 1993; 9: 371-7.
21. Nakane M, Schmidt HH, Pollock JS, Forstermann U, Murad F. Cloned human brain nitric oxide synthase is highly expressed in skeletal muscle. FEBS Lett 1993; 316: 175-80.
22. Salerno JC, Frey C, McMillan K, Williams RF, Masters BS, Griffith OW. Characterization by electron paramagnetic resonance of the interactions of L-arginine and L-thiocitrulline with the heme cofactor region of nitric oxide synthase. J Biol Chem 1995; 270: 27423-8.
23. Mayer B, Koesling D. cGMP signalling beyond nitric oxide. Trends Pharmacol Sci 2001; 22: 546-8.
24. Corbin JD, Francis SH. Cyclic GMP phosphodiesterase-5: target of sildenafil. J Biol Chem 1999 14; 274: 13729-32.
25. Moncada S, Higgs EA. Molecular mechanisms and therapeutic strategies related to nitric oxide. FASEB J 1995; 9: 1319-30.
26. Fukuto JM, Chaudhuri G. Inhibition of constitutive and inducible nitric oxide synthase: potential selective inhibition. Annu Rev Pharmacol Toxicol 1995; 35: 165-94.
27. Griffith OW, Gross SS. Inhibitors of nitric oxide synthases. In: M Feelisch, JS Stamler Ed, Methods in Nitric Oxide Research. Chichester, UK: Wiley, 1996.
28. Bogle RG, Moncada S, Pearson JD, Mann GE. Identification of inhibitors of nitric oxide synthase that do not interact with the endothelial cell L-arginine transporter. Br J Pharmacol 1992; 105: 768-70.
29. Schmidt K, List BM, Klatt P, Mayer B. Characterization of neuronal amino acid transporters: uptake of nitric oxide synthase inhibitors and implication for their biological effects. J Neurochem 1995; 64: 1469-75.
30. Joly GA, Narayanan K, Griffith OW, Kilbourn RG. Characterization of the effects of two new arginine/citrulline analogues on constitutive and inducible nitric oxide synthases in rat aorta. Br J Pharmacol 1995; 115: 491-7.
31. Corbett JA, Tilton RG, Chang K, Hasan KS, Ido Y, Wang JL, et al. Aminoguanidine, a novel inhibitor of nitric oxide formation, prevents diabetic vascular dysfunction. Diabetes 1992; 41: 552-6.
32. Babbedge RC, Bland-Ward PA, Hart SL, Moore PK. Inhibition of rat cerebellar nitric oxide synthase by 7-nitro indazole and related substituted indazoles. Br J Pharmacol 1993; 110: 225-8.
33. Lee QP, Juchau MR. Dysmorphogenic effects of nitric oxide (NO) and NO-synthase inhibition: studies with intra-amniotic injections of sodium nitroprusside and NG-monomethyl-L-arginine. Teratology. 1994; 49: 452-64.
34. Lee QP, Park HW, Thayer J, Mirkes PE, Juchau MR. Apoptosis induced in cultured rat embryos by intra-amniotically microinjected sodium nitroprusside. Teratology 1996; 53: 21-30.
35. Ivankovic S. Absence of a teratogenic effect of sodium nitroprusside in wistar rats and rabbits Arzneimittelforschung. 1979; 29: 1092-94.
36. Salas SP, Altermatt F, Campos M, Giacaman A, Rosso P. Effects of long-term nitric oxide synthesis inhibition in plasma volume expansion and fetal growth in the pregnant rat. Hypertension 1995; 26: 1019-23.
37. Gregg AR, Schauer A, Shi O, Liu Z, Lee CGL, O'Brien WE. Limb reduction defects in endothelial nitric oxide synthase-deficient mice. Am J Physiol 1998; 275: 2319-24.
38. Hefler LA, Reyes CA, O'Brien WE, Gregg AR. Perinatal development of endothelial nitric oxide synthase-deficient mice. Biol Reprod 2001; 64: 666-73.
39. Lee TC, Zhao YD, Courtman DW, Stewart DJ. Abnormal aortic valve development in mice lacking endothelial nitric oxide synthase. Circulation. 2000 101: 2345-8.
40. Feng Q, Song W, Lu X, Hamilton JA, Lei M, Peng T, Yee SP. Development of heart failure and congenital septal defects in mice lacking endothelial nitric oxide synthase. Circulation. 2002; 106: 873-9.
41. Tiboni GM, Lamonaca D. Transplacental exposure to methylene blue initiates teratogenesis in the mouse: preliminary, evidence for a mechanistic implication of cyclic GMP pathway disruption. Teratology 2001; 64: 213-20.
42. Katsuki S, Arnold W, Mittal C, Murad F. Stimulation of guanylate cyclase by sodium nitroprusside, nitroglicerin and nitric oxide in various tissue preparations and comparison to the effects of sodium azide and hydroxylamine. J Cyclic Nucleotide Res 1977; 3: 23-35.
43. Gruetter CA, Barry BK, McNamara DB, Gruetter DY, Kadowitz PJ, Ignarro LJ. Relaxation of bovine coronary artery and activation of coronary arterial guanylate cyclase by nitric oxide, nitroprusside and a carcinogenic nitrosoamine. J Cyclic Nucleotide Res 1979; 5: 211-24.
44. Mayer B, Brunner F, Schmidt K. Inhibition of nitric oxide synthesis by methylene blue. Biochem Pharmacol 1992; 45: 367-74.
45. Luo D, Das S, Vincent SR. Effects of methylene blue and LY83583 on neuronal nitric oxide synthase and NADPH-djaphorase Eur J Pharmacol 1995; 290: 247-51.
46. Brune B, Schmidt KU, Ullrich V. Activation of soluble guanylate cyclase by carbon monoxide and inhibition by superoxide anion. Eur J Biochem 1990; 192: 683-8.
47. Wolin MS, Cherry PD; Rodenburg JM, Messina EJ, Kaley G. Methylene blue inhibits vasodilation of skeletal muscle arterioles to acetylcholine and nitric oxide via the extracellular generation of superoxide anion. J Pharmacol Exp Ther 1990; 254: 872-6.
48. Marczin N, Ryan US, Catravas JD. Methylene blue inhibits nitrovasodilator- and endothelium-derived relaxing factor-induced cyclic GMP accumulation in cultured pulmonary artetial smooth muscle via generation of superoxide anion J Pharmacol Exp Ther 1992; 263: 170-9.
49. Blottner D, Luck G. Nitric oxide synthase (NOS) in mouse skeletal muscle development and differentiated myoblasts. Cell Tissue Res. 1998; 292: 293-302.
50. Robertson CP, Gibbs SM, Roelink H. cGMP enhances the sonic hedgehog response in neural plate cells. Dev Biol 2001; 238: 157-67.
51. Diket AL, Pierce MR, Munshi UK, Voelker CA, Eloby-Childress S, Greenberg SS, et al. Nitric Oxide inhibition causes intrauterine growth retardation and hind-limb disruption in rats. Am J Obstet Gynecol 1994. 171: 1243-50.
52. Pierce RL, Pierce MR, Liu H, Kadowitz PJ, Miller MJS. Limb reduction defects after prenatal inhibition of nitric oxide synthase in rats. Pediatr Res 1995; 38: 905-11.
53. Greenberg SS, Lancaster JR, Xie J, Sarphie TG, Zhao X, Hua L, et al. Effects of NO synthase inhibitors, arginine-deficient diet, and amiloride in pregnant rats. Am J Physiol 1997; 273: 1031-45.
54. L-arginine methyl ester (L-NAME), a nitric oxide synthase inhibitor in rats. Reprod Toxicol 1997; 11: 709-717.
55. ω-nitro-L-arginine methyl ester (L-NAME) causes limb defects in mouse fetuses: protective effect of acute hyperoxia. Pediatr Res 2003; 54: 69-76.
56. Juchau MR. Chemical teratogenesis in humans: biochemical and molecular mechanisms. Prog Drug Res. 1997; 49: 25-92.
57. Tiboni GM, Giampietro F. Inhibition of nitric oxide synthesis causes preterm delivery in the mouse. Human Reprod 2000; 15: 1838-42.
58. Huang PL, Huang Z, Mashimo H, Bloch KD, Moskowitz MA, Bevan JA, et al. Hypertension in mice lacking the gene for, endothelial nitric oxide synthase. Nature 1995; 377: 239-42.
59. Laubach VE, Shesely EG, Smithies O, Sherman PA. Mice lacking inducible nitric oxide synthase are not resistant to lipopolysaccharide-induced death. Proc Natl Acad Sci USA 1995; 92: 10688-92.
60. Wei XQ, Charles IG, Smith A, Ure J, Feng GJ, Huang FP, et al. Altered immune responses in mice lacking inducible nitric oxide synthase. Nature 1995; 375: 408-11.
61. MacMicking JD, Nathan C, Hom G, Chartrain N, Fletcher DS, Trumbauer M, et al. Altered responses to bacterial infection and endotoxic shock in mice lacking inducible nitric oxide synthase. Cell. 1995; 81: 641-50.
62. Huang PL, Dawson TM, Bredt DS, Snyder SH, Fishman MC. Targeted disruption of the neuronal nitric oxide synthase gene. Cell. 1993; 75: 1273-86.
63. Baydoun AR, Mann GE. Selective targeting of nitric oxide synthase inhibitors to system y+ in activated macrophages. Biochem Biophys Res Commun. 1994; 200: 726-31.
64. L-arginine methyl ester). A new mechanistic model of vascular disruption. Teratology 1999; 60: 151-160.
65. Etches PC, Finer NN, Barrington KJ, Graham AJ, Chan WK. Nitric oxide reverses acute hypoxic pulmonary hypertension in the newborn piglet. Pediatr Res 1994; 35: 15-9.
66. Bustamante SA, Pang Y, Romero S, Pierce MR, Voelker CA, Thompson JH, et al. Inducible nitric oxide synthase and the regulation of central vessels caliber in the fetal rat. Circulation 1996; 94: 48-1953.
67. Fantel AG, Person RE. Further evidence for the role of free radicals in the limb teratogenicity of L-NAME. Teratology 2002; 66: 24-32.
68. Leist KH, Grauwiler J. Fetal pathology following uterine-vessel clamping on day 14 of gestation. Teratology 1974; 10: 55-68.
69. Webster WS, Lipson AH, Brown-Woodman PD. Uterine trauma and limb defects. Teratology 1987; 35: 253-60.
70. Danielsson BR, Skold AC, Azarbayjani F. Class III antiarhhythmics and phenytoin: teratogenicity due to embryonic cardiac dysrhythmia and reoxygenation damage. Curr Pharm Des 2001; 7: 787-802.
71. Danielsson BRG, Danielson M, Rundqvist E, Reiland S. Identical phalangeal defects induced by phenytoin and nifedipine suggest fetal hypoxia and vascular disruption behind phenytoin teratogenicity. Teratology 1992; 45: 247-58.
72. Webster WS, Brown-Woodman PDC, Lipson AH, Ritchie HE. Fetal brain damage in the rat following prenatal exposure to cocaine. Neurotoxicol Teratol 1991; 13: 621-26.
73. Fantel AG, Barber CV, Carda MB, Tumbic RW, Mackler B. Studies of the role of ischemia/reperfusion and superoxide anion radical production in the teratogenicity of cocaine. Teratology 1992; 46: 293-300.
74. Danielsson BRG, Reiland S, Rundqvist E, Danielson M. Digital defects induced by vasodilating agents: relationship to uteroplacental blood flow. Teratology 1989; 40: 351-8.
75. Danielsson BRG, Danielson M, Reiland S, Rundqvist E, Dencker L, Regard CG. Histological and in vitro studies supporting decreased uteroplacental blood flow as explanation for digital defects after administration of vasodilators. Teratology 1990; 41: 185-93.
76. Jost A. La dégénerescence des extémités du foetus de rat sous des actions hormonales (acroblapsie expé rimentale) et la théorie des bulles myélencé phaliques de Bonnevie. Arch Franc Pediatr 1953; 10: 865-70.
77. Jost A, Roffi J, Cowitat M. In: Swinyard CA (eds) Limb development and deformity: Congenital amputations determined by the br gene and those induced by adrenaline injection in the rabbit fetus. Problems of evaluation and rehabilitation. Thomas, Springfield, 1969; 187-99.
78. McCann SM, Haens G, Mastronardi C, Walczewska A, Karanth S, Rettori V, et al. The role of nitric oxide (NO) in control of LHRH release that mediates gonadotropin release and sexual behavior. Curr Pharm Design 2003; 9(5): 381-90.
79. Morbidelli L, Donnini S, Ziche M. Role of nitric oxide in the modulation of angiogenesis. Curr Pharm Design 2003; 9(7): 521-30.
80. Salerno L, Sorrenti V, Di Giacomo C, Romeo G, Siracusa MA. Progress in the development of selective nitric oxide synthase (NOS) inhibitors. Curr Pharm Design 2002; 8(3): 177-200.